Double-blind trial of triazolam 0.5 mg vs. nitrazepam 5 mg in outpatients.
In a double-blind, cross-over trial, triazolam (0.5 mg) was compared with nitrazepam (5 mg) in patients with disturbed sleep. Each drug was given once, with a 48-h interval, to 40 outpatients. Quality, duration, and latency of sleep, and number of awakenings during the night, showed a significant difference in favour of triazolam. An overall evaluation of sleep also showed triazolam to be superior to nitrazepam. Both drugs seemed to reduce dream activity and to alter the character of the dreams. There was no significant difference in side effects.
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001143:Arousal / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009567:Nitrazepam / Q000009:adverse effects / Q000627:therapeutic use*; D011930:Reaction Time / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D014229:Triazolam / Q000009:adverse effects / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D014229:Triazolam; D009567:Nitrazepam